Characterizing MICVO’s Anti-Tumor, Immunostimulatory & Synergistic Activity in Immunotherapy-Sensitive & Refractory Tumor Models
- Exploring MICVO targeting EDB+FN, a non-cellular tumor ECM structural component
- Evaluating maMICVO to inhibit tumor growth and modulate the tumor-immune microenvironment in syngeneic tumor models
- Combining maMICVO and anti-PD-1 treatments to demonstrate synergistic anti-tumor activity across syngeneic tumor models, including HNSCC
- Preclinical findings support the ongoing clinical development of MICVO as a monotherapy and in combination with pembrolizumab for R/M HNSCC